Brief: First Wave Biopharma Files IND Application For Enhanced Delivery Formulation Of Adrulipase
30/11/2022 12:22
Nov 30 (Reuters) - First Wave BioPharma Inc FWBI.O :
* FIRST WAVE BIOPHARMA FILES INVESTIGATIONAL NEW DRUG
APPLICATION
FOR ENHANCED MICROGRANULE DELIVERY FORMULATION OF ADRULIPASE
* FIRST WAVE BIOPHARMA INC - UPON IND CLEARANCE, FIRST WAVE
EXPECTS TO INITIATE A PHASE 2 TRIAL AT BEGINNING OF 2023
Source text for Eikon: ID:nGNX61rhgF
Further company coverage: FWBI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GridAI Technologies
See all newsBrief: Gridai Technologies Corp - Enters $2.54 Million Private Placement Of Shares And Warrants - SEC Filing
Brief: IBN Announces Latest Episode Of The Techmediawire Podcast Featuring Marshall Chapin, CEO Of Grid Ai Corp.
Brief: Entero Therapeutics Terminated Interim CEO And Chairman Richard Joel Paolone Effective Immediately - SEC Filing
Brief: Entero Therapeutics Inc - Now Offering 15.2 Million Shares Of Common Stock
Brief: Entero Therapeutics Inc Subsidiary Immunogenx Enters Settlement Agreement